Disease-specific quality indicators, guidelines and outcome measures in scleroderma.
The assessment of the patient with systemic sclerosis remains a challenge for the clinical investigator and the clinician. The measures used to assess the impact of the disease on the quality of life and the outcome measures for both clinical practice and clinical research, including therapeutic trials, are presented and discussed, with emphasis on present limitations.